XNCRXencor, Inc.

$890M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$17M-62.7% YoY

Gross Profit

$14M82.2% margin

Operating Income

-$62M-367.4% margin

Net Income

-$66M-388.9% margin

EPS (Diluted)

$-1.07

QoQ Revenue Growth

+6.0%

Cash Flow

Operating Cash Flow

-$67M

Free Cash Flow

-$71M

Stock-Based Comp.

$17M

Balance Sheet

Total Assets

$826M

Total Liabilities

$264M

Stockholders' Equity

$564M

Cash & Equivalents

$31M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$17M	$46M	-62.7%
Gross Profit	$14M	-$15M	+195.9%
Operating Income	-$62M	-$26M	-139.7%
Net Income	-$66M	-$22M	-200.5%

Revenue Segments

Non-cash Royalty

$9M50%

License Agreement

$9M50%

XNCR Q2 2024 Earnings — Xencor, Inc. Revenue & Financial Results | Market Cap Arena